ストックスクリーナーアプリを入手
2.29
0.00%
0.00
前日終値:
$2.29
開ける：
$2.3
24時間の取引高:
31,234
Relative Volume:
1.07
時価総額：
$69.82M
収益：
$300.00K
当期純損益:
$-40.16M
株価収益率:
-1.7383
EPS:
-1.3174
ネットキャッシュフロー:
$-42.36M
1週間 パフォーマンス:
-0.43%
1か月 パフォーマンス:
-2.55%
6か月 パフォーマンス:
-10.55%
1年 パフォーマンス:
-22.64%
1日の値動き範囲:
$2.28
$2.32
1週間の範囲:
$2.275
$2.4352
52週間の値動き範囲:
$2.09
$3.61
Xbiotech Inc Stock (XBIT) Company Profile
Compare XBIT vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
XBIT
Xbiotech Inc
|
2.29 | 69.82M | 300.00K | -40.16M | -42.36M | -1.3174 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Xbiotech Inc Stock (XBIT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2019-06-14 | 開始されました | Piper Jaffray | Overweight |
| 2017-04-21 | ダウングレード | Noble Financial | Buy → Hold |
| 2016-06-28 | 繰り返されました | Noble Financial | Buy |
Xbiotech Inc (XBIT) 最新ニュース
XBiotech Inc. (XBIT) Slides 2.97% as Shares Approach Key Support at $2.18Pairs Trade - dars.gov.et
XBiotech focuses on antibody pipeline as biotech sector evolves - ad-hoc-news.de
ETFs Investing in XBiotech, Inc. Stocks - TradingView
XBiotech, Inc. Actuals & Estimates (SWB:4XB) - TradingView
XBiotech, Inc. Actuals & Estimates (LS:A14QF1) - TradingView
XBiotech, Inc. Actuals & Estimates (MUN:4XB) - TradingView
XBiotech, Inc. Actuals & Estimates (FWB:4XB) - TradingView
Price to earnings forward of XBiotech Inc. – NASDAQ:XBIT - TradingView
XBiotech, Inc. Actuals & Estimates (NASDAQ:XBIT) - TradingView
Price to sales forward of XBiotech Inc. – NASDAQ:XBIT - TradingView
XBiotech, Inc. Actuals & Estimates (DUS:4XB) - TradingView
XBiotech, Inc. Actuals & Estimates (BX:4XB) - TradingView
Enterprise value to revenue forward of XBiotech Inc. – NASDAQ:XBIT - TradingView
XBiotech, Inc. Actuals & Estimates (BOATS:XBIT) - TradingView
Price to book forward of XBiotech Inc. – NASDAQ:XBIT - TradingView
Enterprise value to EBIT forward of XBiotech Inc. – NASDAQ:XBIT - TradingView
XBiotech Inc (XBIT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
XBiotech to commence V-SPINE trial enrolment for vilamakitug - MSN
XBiotech Inc. (XBIT) Nears Key Support After 2.5% DeclineAdvance Decline Volume - dars.gov.et
XBiotech Inc (XBIT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
XBiotech Inc (XBIT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
XBiotech Inc (XBIT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
XBiotech Inc (XBIT) Valuation: PE, PB & Fair Value Analysis - TradingKey
XBiotech Inc (XBIT) Institutional Confidence - TradingKey
XBiotech Inc (XBIT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
XBiotech Inc (XBIT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
XBiotech Inc (XBIT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
XBIT Earnings Overview 2026-06-16Profit Warning Alert - dars.gov.et
XBiotech Receives Authorization for V-SPINE Trial - Intellectia AI
XBiotech Inc Stock (US9840001002): FDA clears Phase II V-SPINE trial for vilamakitug in axial spondy - AD HOC NEWS
XBiotech (XBIT) Receives FDA Nod for V-SPINE Study - GuruFocus
XBiotech clears FDA review for axial spondyloarthritis study - Investing.com
XBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial Spondyloarthritis - Yahoo Finance UK
XBiotech Inc. (XBIT) Holds Near Support Amidst Minor DeclinesDescending Triangle - newsline.com
XBIT Should I Buy - Intellectia AI
XBiotech Inc stock (US9840001002): shares little changed as investors await next earnings update - Ad-hoc-news.de
XBiotech Inc. (XBIT) Slips 2.27% as Stock Tests Key Support LevelsMotive Wave - The Legal Advocate
XBITXBiotech Inc Dividends - Finviz
XBiotech Inc. (XBIT) Edges Higher, Approaching Key Resistance at $2.56Trading Ideas - The Legal Advocate
XBiotech Inc. (XBIT) Edges Higher on Modest Volume, Tests Resistance Near $2.58Composite Profile - The Legal Advocate
XBIT | XBiotech Inc Insider Trading - Quiver Quantitative
XBiotech stock (US9840001002): Clinical-stage biotech stays in focus - AD HOC NEWS
XBiotech: Q1 Earnings Snapshot - Stamford Advocate
XBiotech Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
XBiotech (NASDAQ: XBIT) trims Q1 2026 loss, holds $115.5M cash and cuts R&D spend - Stock Titan
XBiotech’s New Axial Spondyloarthritis Trial Puts Vilamakitug on Investors’ Radar - TipRanks
TradingKey - TradingKey
Number of shareholders of XBiotech, Inc. – FWB:4XB - TradingView
XBiotech (XBIT) Projected to Post Earnings on Tuesday - MarketBeat
XBIT (XBiotech) reports zero Q1 2020 EPS missing estimates, shares dip 0.78 percent amid investor concern.Post Announcement - newser.com
XBiotech Inc. 2025 Executive Compensation, Board Structure, and Shareholder Ownership Overview - Minichart
Xbiotech Inc (XBIT) 財務データ
収益
当期純利益
現金流量
EPS
2.64%
大文字化:
|
ボリューム (24 時間):